#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2019 - 12

Atherosclerosis in patients with type 1 diabetes

Czech version

Authors: David Karásek
Authors‘ workplace: II. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
Published in: Vnitř Lék 2019; 65(12): 775-782
Category:

Overview

Type 1 diabetes is often associated with the early manifestation of atherosclerosis, which represents the morphological basis for macrovascular complications of diabetics. Atherosclerosis in patients with type 1 diabetes shows certain specific features that result from different proportions of risk factors, the presence of diabetes and its complications. The paper deals with the possibilities of influencing and detecting the atherosclerotic process in these risk patients.

Keywords:

Atherosclerosis – diabetic kidney disease – dyslipidemia – hypertension – obesity – type 1 diabetes

Sources
  1. Diabetologie, péče o diabetiky. Ústav zdravotnických informací a statistiky ČR. Dostupné z WWW: <https://www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/diabetologie-pece-diabetiky>.
  2. Schofield J, Ho J, Soran H. Cardiovascular. Risk in Type 1 Diabetes Mellitus. Diabetes Ther 2019; 10(3): 773–789. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–019–0612–8>.
  3. Huxley RR, Peters SA, Mishra GD et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015; 3(3): 198–206. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(14)70248–7>.
  4. Soedamah-Muthu SS, Fuller JH et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006; 29(4): 798–804. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.29.04.06.dc05–1433>.
  5. Harjutsalo V, Thomas MC, Forsblom C et al. FinnDiane Study Group. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab 2018; 20(12): 2759–2767. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13456>.
  6. Larsson SC, Wallin A, Håkansson N et al. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol 2018; 262: 66–70. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2018.03.099>.
  7. Cleary PA, Orchard TJ, Genuth S et al. [DCCT/EDIC Research Group]. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55(12): 3556–3565. Dostupné z DOI: <http://dx.doi.org/10.2337/db06–0653>.
  8. Holte KB, Svanteson M, Hanssen KF et al. Undiagnosed coronary artery disease in long-term type 1 diabetes. The Dialong study. J Diabetes Complications 2019; 33(5): 383–389. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2019.01.006>.
  9. Karásek D. Diabetická dyslipidemie. Maxdorf: Praha 2018. ISBN 978–80–7345–556–9.
  10. Kanter JE, Johansson F, LeBoeuf RC et al. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 2007; 100(6): 769–781. Dostupné z DOI: <http://dx.doi.org/10.1161/01.RES.0000259589.34348.74>.
  11. Djaberi R, Schuijf JD, Boersma E et al. Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography. Diabetes Care 2009; 32(8): 1507–1512. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–0320>.
  12. de Ferranti SD, de Boer IH, Fonseca V et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014; 37(10): 2843–2863. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–1720>.
  13. Kearney PM, Blackwell L, Collins R et al. [Cholesterol Treatment Trialists‘ (CTT) Collaborators]. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60104-X>.
  14. Mach F, Baigent C, Catapano AL et al. [ESC Scientific Document Group]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; pii: ehz455. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.
  15. Cosentino F, Grant PJ, Aboyans V et al. [ESC Scientific Document Group]. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019; pii: ehz486. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
  16. Lee SI, Patel M, Jones CM et al. Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. Ther Adv Chronic Dis 2015; 6(6): 347–374. Dostupné z DOI: <http://dx.doi.org/10.1177/2040622315598502>.
  17. Nathan DM, Bayless M, Cleary P et al. [DCCT/EDIC Research Group]. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013; 62(12): 3976–3986. Dostupné z DOI: <http://dx.doi.org/10.2337/db13–1093>.
  18. Chillarón JJ, Sales MP, Flores-Le-Roux JA et al. Insulin resistance and hypertension in patients with type 1 diabetes. J Diabetes Complications 2011; 25(4): 232–236. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2011.03.006>.
  19. Williams B, Mancia G, Spiering W et al. [ESC Scientific Document Group]. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021–3104. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy339>.
  20. [American Diabetes Association]. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41(Suppl. 1): S105-S118. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18-S010>.
  21. Pan A, Wang Y, Talaei M et al. Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation 2015; 132(19): 1795–1804. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017926>.
  22. Nathan DM, Zinman B, Cleary PA et al. [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group]. Modern-day clinical course of type 1 diabetes mellitus after 30 years‘ duration: the diabetes kontrol and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009; 169(14): 1307–1316. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2009.193>.
  23. Schechter R, Reutrakul S. Management of Severe Insulin Resistance in Patients with Type 1 Diabetes. Curr Diab Rep 2015; 15(10): 77. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–015–0641–2>.
  24. Gingras V, Leroux C, Fortin A et al. Predictors of cardiovascular risk among patients with type 1 diabetes: A critical analysis of the metabolic syndrome and its components. Diabetes Metab 2017; 43(3): 217–222. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabet.2016.10.007>.
  25. Merger SR, Kerner W, Stadler M et al. DPV Initiative; German BMBF Competence Network Diabetes mellitus. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract 2016; 119: 48–56. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2016.06.003>.
  26. Bramante CT, Lee CJ, Gudzune KA. Treatment of Obesity in Patients With Diabetes. Diabetes Spectr 2017; 30(4): 237–243. Dostupné z DOI: <http://dx.doi.org/10.2337/ds17–0030>.
  27. Ranjan A, Schmidt S, Damm-Frydenberg C et al. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: a randomized open-label crossover trial. Diabetes Obes Metab 2017; 19(10): 1479–1484. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12953>.
  28. Schoenaker DA, Toeller M, Chaturvedi N et al. [EPCS Group]. Dietary saturated fat and fibre and risk of cardiovascular disease and all-cause mortality among type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2012; 55(8): 2132–2141. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–012–2550–0>.
  29. Yardley JE, Hay J, Abou-Setta AM et al. A systematic review and meta-analysis of exercise interventions in adults with type 1 diabetes. Diabetes Res Clin Pract 2014; 106(3): 393–400. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2014.09.038>.
  30. Chimen M, Kennedy A, Nirantharakumar K et al. What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 2012; 55(3): 542–551. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–011–2403–2>.
  31. Kirwan JP, Aminian A, Kashyap SR et al. Bariatric Surgery in Obese Patients With Type 1 Diabetes. Diabetes Care 2016; 39(6): 941–948. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–2732>.
  32. Höskuldsdottir G, Ekelund J, Miftaraj M et al. Type 1 diabetes and obesity: Could bariatric surgery be safe and beneficial option? Presented at: European Association for the Study of Diabetes Annual Meeting; Sept. 16–20, 2019. Barcelona, Spain.
  33. Liu C, Wu D, Zheng X et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(12): 142–148. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2014.0190>.
  34. Petrie JR, Chaturvedi N, Ford I et al. [REMOVAL Study Group]. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5(8): 597–609. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30194–8>.
  35. Zelniker TA, Wiviott SD, Raz I et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 2019; 139(17): 2022–2031. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038868>.
  36. Khat DZ, Husain M. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. Curr Diab Rep 2018; 18(7): 45. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892–018–1011–7>.
  37. Chen J, Fan F, Wang JY et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017; 7: 44128. Dostupné z DOI: <http://dx.doi.org/10.1038/srep44128>.
  38. Llano A, McKay G, Fisher M. SGLT inhibitors for people with type 1 diabetes. Prac Diabetes 2019. Dostupné z DOI: <https://doi.org/10.1002/pdi.2222>.
  39. Wang W, Gao Y, Chen D et al. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract 2017; 129: 213–223. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2017.05.007>.
  40. Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm 2019; 76(21): 1739–1748. Dostupné z DOI: <http://dx.doi.org/10.1093/ajhp/zxz179>.
  41. Gæde P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59(11): 2298–2307. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–4065–6>.
  42. [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group]. Risk Factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes 2016; 65(5): 1370–1379. Dostupné z DOI: <http://dx.doi.org/10.2337/db15–1517>.
  43. Bo Hyun Kim BH, Son SM. Mechanism of Developing Diabetic Vascular Complication by Oxidative Stress. J Korean Endocr Soc 2006; 21(6): 448–459. Dostupné z DOI: <https://doi.org/10.3803/jkes.2006.21.6.448>.
  44. [Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group]. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care 2016; 39(5): 686–693. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1990>.
  45. Steineck I, Cederholm J, Eliasson B et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ 2015; 350: h3234. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.h3234>.
  46. Patti G, Cavallari I, Andreotti F et al. Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019; 16(2): 113–130. Dostupné z DOI: <http://dx.doi.org/10.1038/s41569–018–0080–2>.
Labels
Diabetology Endocrinology Internal medicine
Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk”
Hyperlipidemia management in Slovakia: observational study
Vascular age
Úvodník
Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019
Hypertriglyceridemia and atherosclerosis risk
Extermination of atherosclerosis not only in lower extremities
Atherosclerosis and beta-blockade: A forgotten option?
Pharmacologically induced thyreopathy in patients with cardiovascular disease
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill
Ľubomíra Fábryová, Pavol Holéczy a kolektív. Diabezita. Diabetes a obezita: nerozlučné dvojičky
Article was published in

Internal Medicine

Issue 12
2019 Issue 12
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#